Dyno Therapeutics announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease. The capsid license follows an ...

We believe, and have now demonstrated, that gene therapy is ... to other monogenic neurologic and muscle diseases with a scalable platform based on a recombinant AAV9 vector.

has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. The capsid license is pursuant to the agreement between ...